Check for updates

OPEN ACCESS

EDITED BY Che Kang Lim, Singapore General Hospital, Singapore

REVIEWED BY Mario Ernesto Cruz-Munoz, Universidad Autónoma del Estado de Morelos, Mexico Sinem Firtina, University of Istinye, Türkiye

*CORRESPONDENCE Wei Shi, ⊠ shiwei@csu.edu.cn

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION

This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics

RECEIVED 03 December 2022 ACCEPTED 27 February 2023 PUBLISHED 16 March 2023

CITATION

Deng S, Rao S, Wang AR and Shi W (2023), Case report: Rubella virus-induced cutaneous granulomas in a girl with atypical SCID caused by *DCLRE1C* gene mutations. *Front. Genet.* 14:1115027. doi: 10.3389/fgene.2023.1115027

COPYRIGHT

© 2023 Deng, Rao, Wang and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Case report: Rubella virus-induced cutaneous granulomas in a girl with atypical SCID caused by *DCLRE1C* gene mutations

Sihan Deng^{1†}, Shijia Rao^{2†}, Alun R. Wang³ and Wei Shi^{1,4}*

¹Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China, ²Department of Dermatology, The Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, China, ³Department of Pathology, Tulane University School of Medicine, New Orleans, LA, United States, ⁴National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China

Here, we report a case of rubella virus-induced granulomatous dermatitis in a young girl with immunodeficiency caused by *DCLRE1C* gene mutations. The patient was a 6-year-old girl who presented with multiple erythematous plaques on the face and limbs. Biopsies of the lesions revealed tuberculoid necrotizing granulomas. No pathogens could be identified on extensive special stains, tissue cultures, or PCR-based microbiology assays. Metagenomic next-generation sequencing analysis revealed the rubella virus. Underlying atypical severe combined immunodeficiency was recognized based on the patient's history of repetitive infections since birth, low T-cell, B-cell, and NK cell counts, and abnormal immunoglobulins and complements. Whole-exome sequencing revealed the genetic abnormality of the atypical severe combined immunodeficiency (SCID), and compound heterozygous mutations of the *DCLRE1C* gene were detected. This report highlights the diagnostic values of metagenomic next-generation sequencing in identifying rare pathogens causing cutaneous granulomas in patients with atypical SCID.

KEYWORDS

next-generation sequencing, rubella virus, whole-exome sequencing, *DCLRE1C* gene, granulomatous, severe combined immunodeficiency syndrome

1 Introduction

Cutaneous granulomatous dermatitis is a common disorder that can be divided into infectious and non-infectious etiologies. Infection should be ruled out if no clear cause is identified, especially in immunocompromised patients. Even if an infectious etiology is suspected, the causal microorganisms are often unidentifiable. The prevalence of granulomas is rather high among patients with combined immune deficiency and other types of immunodeficiencies. Skin represents a primary site of granulomas in patients with combined immune deficiency. Some granulomas are caused by the rubella virus infection. The traditional ways of identifying microorganisms are based on morphology, histochemistry, and cultures with limited sensitivity and efficiency. Targeted PCR assays developed in recent years have improved sensitivity significantly. Metagenomic nextgeneration sequencing (mNGS) is an unbiased assay that identifies a broad spectrum of



FIGURE 1

RuV infection-induced cutaneous granulomatous dermatitis. Erythematous plaques on cheeks at visit (A) and after 10-month follow-up (B). (C) Dense lymphohistiocytic infiltrate in the dermis forming a nodule. (D) Necrotizing granulomas in the deep dermis.

pathogens, including many rare pathogens. Mutations in the DCLRE1C gene have been documented to cause immunodeficiency with phenotypes ranging from severe combined immunodeficiency to mere antibody deficiency. The whole-exome sequencing technique is an effective tool in revealing underlying molecular mechanisms causing immunodeficiencies.

2 Manuscript

2.1 Case description

A 6-year-old girl presented with facial erythematous plaques that had gradually spread into her limbs over the course of a year (Figure 1A). The center of some erythematous plaques was ulcerated and scabbed spontaneously. She appeared to be predisposed to respiratory infections since birth. Multiple biopsies of the plaques revealed necrotizing granulomatous inflammation (Figure 1D). No microorganisms were identified on PAS and acid-fast stains, tissue cultures, and PCR assays for fungi and mycobacteria. Dense lymphocyte infiltrate with lymphoid follicle formation in the dermis with adnexal involvement was also found in a biopsy from the left upper arm (Figure 1C). Most lymphocytes were T-cells (CD3⁺) with mixed CD4⁺ and CD8⁺ cells. Some lymphocytes showed mild cytological atypia. Clonal expansion of the T-cell population was detected through T-cell receptor gene rearrangement studies. The patient had neutropenia and lymphopenia of T cells, B cells, and NK cells. Specifically, cell counts of CD3⁺ T cells, CD4⁺ T cells, and CD8⁺ T cells were all lower than normal. Subpopulations of the CD3+/CD8-/IL-4+ lymphocytes and CD3+/CD8-/IFN- γ + lymphocytes were higher than normal, and CD3+/CD4+/CD25+/FOXP3+ lymphocytes and CD3+/CD8-/IL-17A + lymphocytes were lower than normal. Serum IgA and IgM levels were significantly lower, and the patient's C3 level was slightly lower than normal (Table 1). No clinically significant nodular metabolic enhancement was observed on PET-CT. The timeline of the patient's care is summarized in Figure 2.

Because mycobacterial infections were not ruled out, a diagnostic therapeutic 8-week course of quadruple antituberculosis therapy was performed but without effect. Repeated metagenomic DNA and RNA mNGS analyses were performed, and rubella virus (RuV, read 7280) was detected. A serology test showed RuV IgM was 1.41 S/CO (positive range: \geq 1), and the RuV IgG titer was 243.7 IU/mL (positive range: \geq 10). Therefore, a diagnosis of rubella virus-induced cutaneous granulomatous dermatitis was reached.

	Result	Normal range
CD3 ⁺ lymphocytes (%)	34.93	50-84
CD3 ⁺ CD4 ⁺ lymphocytes (%)	51.11	30.00-67.00
CD3 ⁺ CD8 ⁺ lymphocytes (%)	41.19	23.00-50.00
CD3 ⁺ CD8 ⁻ lymphocytes (%)	58.81	50.00-75.00
CD3 ⁺ CD8-IL-4+ lymphocytes (%)	3.86	0.30-2.20
CD3 ⁺ CD8-IFN-γ lymphocytes+ (%)	38.06	6.50-28.00
CD3 ⁺ CD4 ⁺ CD25+FOXP3+ lymphocytes (%)	3.25	4.10-9.40
CD3 ⁺ CD8-IL-17A + lymphocytes (%)	0.65	0.20-2.40
CD4 ⁺ cell (/uL)	258	550-1,440
CD8 ⁺ cell (/uL)	185	320-1,250
B lymphocyte (%)	3.62	5-18
B lymphocyte (/uL)	23	90-560
NK cell (/uL)	128	150-1,100
Total T lymphocyte (/uL)	486	955-2,860
C3 (g/L)	0.6	0.7-1.4
C4 (g/L)	0.215	0.1-0.4
IgG (g/L)	5.59	5.4-13.4
IgM (g/L)	0.11	0.43-1.52
IgA (g/L)	0.12	0.3-1.48
IgE (IU/mL)	1	0-100
Blood routine		
WBC (×109/L)	2.52	3.5-9.5
Neutrophils (×109/L)	1.44	1.8-6.3
Lymphocytes (×109/L)	0.49	1.1-3.2
Monocytes (%)	12.7	3-10

TABLE 1 Partial laboratory results of this patient.

In bold: values above or below the reference range.

Considering RuV-associated granulomas are rare and almost exclusively occur in the context of immune deficiency, and the patient had signs of immunodeficiency, a whole- exome sequencing was performed, and heterozygous mutations in *DCLRE1C* gene as c.352G>T (p.G118X) and c.328C>G (p.L110V) were detected 10.3389/fgene.2023.1115027

(Figure 3). It was concluded that hypomorphic heterozygous mutations of *DCLRE1C* genes led to an atypical SCID in this girl, who developed RuV-induced cutaneous granulomatous dermatitis, likely after inoculation with the rubella virus through vaccination. The patient had been waiting for hematopoietic stem-cell transplantation (HSCT) for the previous 10 months, and no other treatments had been initiated. An increase in the number and size of plaques on her face and limbs had been noted (Figure 1B), and the plaques had remained asymptomatic. The patient was hospitalized for pre-transplant examination and preparation.

2.2 Discussion

Here, we report the first Chinese patient with RuV-induced cutaneous tuberculoid necrotizing granulomas in an immunodeficient child with heterozygous *DCLRE1C* gene mutations. Our patient received an MMR vaccine injection when she was 18 months old. The lesions were likely induced by vaccine-derived live attenuated rubella viruses. In addition, a clonal expansion of the T-cell population in the granulomatous lesions was detected. No obvious evidence of a cutaneous T-cell lymphoma was identified. However, it has been observed that immunodeficiency could lead to a clonal expansion of lymphocyte populations, potentially as an autoreactive proliferation of T cells in response to infections or autoantigens, as likely happened in this patient (Herber et al., 2020).

In 2014, vaccine-derived rubella virus was identified from cutaneous granulomas in patients with primary immunodeficiency (Bodemer et al., 2014). Since then, no more than 100 cases have been reported worldwide, mostly in European and American populations. Pathologically, RuV infections could present as necrotizing granulomas, although they can also present as non-specific dermal chronic inflammation (Buchbinder et al., 2019). Skin lesions have been documented to develop several years on average after measles-mumps-rubella (MMR) vaccination, for which attenuated rubella virus is administered. Wild-type RuV has also been detected much less often in granulomatous lesions (Shields et al., 2021).

Based on the reported cases, all RuV-associated granuloma patients present with some degree of immune deficiency, although some are clinically immunocompetent adults (Wanat et al., 2022). Many patients





have DNA repair defects, with *DCLRE1C* gene mutations as one of the causes. *DCLRE1C* encodes ARTEMIS, which is essential in the V(D)J recombination of the immunoglobulin and T-cell receptor genes in T-and B-cell development, as well as in DNA repair (Felgentreff et al., 2015). Mutations in the *DCLRE1C* gene can lead to severe combined immunodeficiency, Omenn syndrome, and radiosensitivity (Strubbe et al., 2021). Severe combined immunodeficiency is an inherited, most severe form of primary immunodeficiency caused by mutations in genes involved in lymphocyte development and function and characterized by the absence or dysfunction of T lymphocytes. It affects both cellular and humoral adaptive immunity. B lymphocytes and NK cells may be affected as well. Over 20 different molecular defects are documented. These include defects in genes involved in antigen receptor gene rearrangement, T-cell receptor signaling, T-cell differentiation, thymic development, and thymic egress of T cells.

Patients with hypomorphic mutations, however, may present with less severe clinical phenotypes depending on residual activity levels on the alleles, causing so-called leaky or atypical SCID (Felgentreff et al., 2015). Atypical SCID occurs and may be defined as a primary immunodeficiency disease secondary to hypomorphic mutations in SCID-causing genes with a milder presentation and higher T-cell counts than typical SCID. The T-cell count is generally above 100/ μ L (Felgentreff et al., 2011). In atypical SCID, patients usually survive beyond 12 months of age. Atypical SCID has been diagnosed in all age groups, frequently significantly later than SCID.

Our patient had a long history of repetitive respiratory tract infections and recurrent nasal stuffiness since birth. These infections are generally not severe and could be alleviated after a few days on antibiotics. A high copy number of Epstein–Barr virus (EBV) DNA was detected in her serum, which would be an indicator that the patient was experiencing an active EBV infection. The patient presented with reduced numbers of peripheral T cells, B cells, NK cells, and neutrophils, and low IgM and IgA levels. Despite these abnormalities, she seemed relatively normal in development and overall health. Her conditions, therefore, fit into atypical SCID.

The pathogenesis of overall white blood cells and immunoglobulin abnormalities caused by *DCLRE1C* gene mutations remains unknown. Usually, the *DCLRE1C* gene variants cause T⁻/B⁻/NK⁺ SCID. However, our patient presents with a unique T⁻/B⁻/NK⁻ phenotype. She presents with a novel compound heterozygosity of two mutations, c.352G>T and c.328C>G. Mutation of c.352G>T (p.G118X) is a nonsense mutation that would very likely result in gene dysfunction. No mutation of this site has been reported in the database, and the ClinVar database assesses it as pathogenic. The clinical significance of mutation of c.328C>G (p.L110V) is uncertain according to ACMG guidelines. Mutations at this location have been reported, although clinical phenotypes (Shahbazi et al., 2019; Xiao et al., 2021). The presence of compound mutations could make a clear correlation between particular genotypes and phenotypes difficult or impossible.

There are no effective conventional therapies for RuV-associated granulomatous diseases. The efficacy of antiviral therapy, TNF- α , IL-1R antagonists, and glucocorticoids remains uncertain (Perelygina et al., 2021). HSCT is considered a curative treatment, and the treatment is more likely to succeed when it is performed early in the disease process. The caveat is that patients with Artemis-deficient immunodeficiency have a decreased tolerance to the alkylating agents used as preparative regimens for HSCT and that carry a risk of significant long-term toxicity (Schuetz et al., 2014). Therefore, it is important to explain the benefits and risks of HSCT in detail to the patients or their parents. Hematopoietic stem cell transplantation is underway for our patient.

Metagenomic next-generation sequencing is a powerful new platform that can simultaneously identify genetic material from entirely different kingdoms of organisms. It can sequence all nucleic acids in a sample and identify multiple populations of microorganisms from different taxa and their proportions. The potential clinical applications are tremendous, particularly in the diagnosis of infectious diseases. As a less biased, sensitive, and broad-spectrum assay, it opens doors for revealing pathogens in numerous unsolvable cases per traditional methodologies.

Data availability statement

The data sets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: https://www.ncbi.nlm.nih.gov/, PRJNA905930.

Ethics statement

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

WS was responsible for planning this work. SD and SR were responsible for drafting this manuscript. WS and AW were

References

Bodemer, C., Sauvage, V., Mahlaoui, N., Cheval, J., Couderc, T., Leclerc-Mercier, S., et al. (2014). Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. *Clin. Microbiol. Infect.* 20 (10), O656–O663. doi:10.1111/ 1469-0691.12573

Buchbinder, D., Hauck, F., Albert, M. H., Rack, A., Bakhtiar, S., Shcherbina, A., et al. (2019). Rubella virus-associated cutaneous granulomatous disease: A unique complication in immune-deficient patients, not limited to DNA repair disorders. *J. Clin. Immunol.* 39 (1), 81–89. doi:10.1007/s10875-018-0581-0

Felgentreff, K., Lee, Y. N., Frugoni, F., Du, L., van der Burg, M., Giliani, S., et al. (2015). Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency. *J. Allergy Clin. Immunol.* 136 (1), 140–150. doi:10.1016/j.jaci.2015.03.005

Felgentreff, K., Perez-Becker, R., Speckmann, C., Schwarz, K., Kalwak, K., Markelj, G., et al. (2011). Clinical and immunological manifestations of patients with atypical severe combined immunodeficiency. *Clin. Immunol.* 141 (1), 73–82. doi:10.1016/j.clim.2011.05.007

Herber, M., Mertz, P., Dieudonné, Y., Guffroy, B., Jung, S., Gies, V., et al. (2020). Primary immunodeficiencies and lymphoma: A systematic review of literature. *Leuk. Lymphoma* 61 (2), 274–284. doi:10.1080/10428194.2019.1672056

Perelygina, L., Faisthalab, R., Abernathy, E., Chen, M. H., Hao, L., Bercovitch, L., et al. (2021). Rubella virus infected macrophages and neutrophils define patterns of granulomatous inflammation in inborn and acquired errors of immunity. *Front. Immunol.* 12, 796065. doi:10.3389/fimmu.2021.796065

responsible for revising this manuscript. WS was responsible for the final approval of the article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2023.1115027/ full#supplementary-material

Schuetz, C., Neven, B., Dvorak, C. C., Leroy, S., Ege, M. J., Pannicke, U., et al. (2014). SCID patients with ARTEMIS vs RAG deficiencies following HCT: Increased risk of late toxicity in ARTEMIS-deficient SCID. *Blood* 123 (2), 281–289. doi:10.1182/blood-2013-01-476432

Shahbazi, Z., Yazdani, R., Shahkarami, S., Shahbazi, S., Hamid, M., Sadeghi-Shabestari, M., et al. (2019). Genetic mutations and immunological features of severe combined immunodeficiency patients in Iran. *Immunol. Lett.* 216, 70–78. doi:10.1016/j.imlet.2019.10.001

Shields, B. E., Perelygina, L., Samimi, S., Haun, P., Leung, T., Abernathy, E., et al. (2021). Granulomatous dermatitis associated with rubella virus infection in an adult with immunodeficiency. *JAMA Dermatol* 157 (7), 842–847. doi:10.1001/jamadermatol. 2021.1577

Strubbe, S., De Bruyne, M., Pannicke, U., Beyls, E., Vandekerckhove, B., Leclercq, G., et al. (2021). A novel non-coding variant in DCLRE1C results in deregulated splicing and induces SCID through the generation of a truncated ARTEMIS protein that fails to support V(D)J recombination and DNA damage repair. *Front. Immunol.* 12, 674226. doi:10.3389/fimmu.2021.674226

Wanat, K. A., Perelygina, L., Chen, M. H., Hao, L., Abernathy, E., Bender, N. R., et al. (2022). Association of persistent rubella virus with idiopathic skin granulomas in clinically immunocompetent adults. *JAMA Dermatol* 158 (6), 626–633. doi:10.1001/jamadermatol.2022.0828

Xiao, F., Lu, Y., Wu, B., Liu, B., Li, G., Zhang, P., et al. (2021). High-frequency exon deletion of DNA cross-link repair 1C accounting for severe combined immunodeficiency may Be missed by whole-exome sequencing. *Front. Genet.* 12, 677748. doi:10.3389/fgene.2021.677748